Dear Doctor Letter (Rote-Hand-Brief) on Nplate® (romiplostim): Possible risk of thrombotic/thromboembolic events
2010.12.15
Active substance: romiplostin
Important safety-relevant information for medical experts regarding the revised dose adjustment in patients with immune thrombocytopenic purpura (ITP) as well as the warnings for administration in ITP patients with hepatic impairment.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN